Your browser doesn't support javascript.
loading
Incidence of acute haemolytic transfusion reaction among ABO-incompatible recipients transfused with A3 blood: A case series.
Latour, Catherine; Gaussen, Amaury; Beaudoin, Julie; Leiva-Torres, Gabriel André; Rochette, Samuel; Robitaille, Nancy.
Afiliação
  • Latour C; Transfusion Medicine, Héma-Québec, Montréal, Quebec, Canada.
  • Gaussen A; Medical Affairs and Innovation, Héma-Québec, Québec City, Quebec, Canada.
  • Beaudoin J; Quality Control and Development, Héma-Québec, Montréal, Quebec, Canada.
  • Leiva-Torres GA; Transfusion Medicine, Héma-Québec, Montréal, Quebec, Canada.
  • Rochette S; Medical Affairs and Innovation, Héma-Québec, Montréal, Quebec, Canada.
  • Robitaille N; Transfusion Medicine, Héma-Québec, Montréal, Quebec, Canada.
Vox Sang ; 118(10): 854-862, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37589206
BACKGROUND AND OBJECTIVES: ABO antigens are among the most immunogenic, but the haemolytic risks of ABO incompatibilities involving a donor with a weak ABO phenotype are little documented. MATERIALS AND METHODS: This retrospective case series assessed the incidence of acute haemolytic transfusion reaction (AHTR) among ABO-incompatible recipients of A3 blood in Québec (Canada). Transfusion safety officers reported laboratory AHTR indicators measured ≤24 h pre- and post-transfusion. Because the AHTR case definition of Québec's Hemovigilance System (QHS) leaves significant room for clinical judgement, a two-step approach was used to assess potential cases: Step 1 consisted in a highly sensitive-but unspecific-initial screen that identified all candidate cases per QHS case definition, and Step 2 consisted in a detailed review of candidate cases by two haematologists. RESULTS: Nine donors initially typed as Group B (N = 1) or O (N = 8) were subsequently found to display an A3 B or A3 O phenotype. Eighty-one recipients received ABO-incompatible blood, including 53 (65.4%) with interpretable data. Of these, 29 (54.7%) were classified as candidate cases after Step 1. Following Step 2, no conclusive evidence of AHTR was found: Abnormal pre- versus post-transfusion changes appeared modest, within normal range, insufficient to ascertain AHTR, or were consistent with a pre-existing condition unrelated to AHTR. Two candidate cases had a QHS-reported transfusion reaction; both were unrelated to AHTR. CONCLUSION: In this case series, no conclusive evidence of serious AHTR was found among ABO-incompatible recipients who were inadvertently transfused with A3 blood.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Incompatibilidade de Grupos Sanguíneos / Reação Transfusional Tipo de estudo: Incidence_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Incompatibilidade de Grupos Sanguíneos / Reação Transfusional Tipo de estudo: Incidence_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article